Full-Time

Clinical Research Coordinator

Posted on 8/30/2025

Iterative Health

Iterative Health

51-200 employees

AI-powered polyp detection for colorectal cancer

No salary listed

Bellevue, WA, USA

In Person

Category
Biology & Biotech (2)
,
Required Skills
Inventory Management
Word/Pages/Docs
Google Cloud Platform
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • High school diploma or GED; Associates degree preferred
  • Minimum 1-2 years of clinical research experience
  • Knowledge of grammar, spelling, and punctuation
  • Knowledge of purchasing, budgeting, and inventory control
  • Skill in taking and transcribing dictation and operating office equipment
  • Skill in answering the phone and responding to questions
  • Skill in time management, prioritization, and multitasking
  • Skill in writing and communicating effectively
  • Ability to work under pressure, communicate and present information
  • Ability to read, interpret, and apply clinic policies and procedures
  • Ability to identify problems, recommend solutions, organize and analyze information
  • Ability to multi-task, establish priorities, and coordinate work activities
  • Ability to competently use Microsoft Office, including Word, PowerPoint, Excel, and appropriate practice management software
  • Must be able to lift up to 25 lbs
  • Must be able to travel and have a valid Motor Vehicle Record (MVR)
Responsibilities
  • Communicate study requirements to all individuals involved in the study.
  • Develop and implement recruitment strategies in accordance with Impact Research and IRB requirements and approvals.
  • Screen subjects for eligibility using protocol specific inclusion and exclusion criteria.
  • Entry of participant information and study visit procedures into the Clinical Trial Management System to ensure billing to appropriate funding source.
  • Maintains adequate inventory of study supplies. When handling investigational drugs/devices, follows the sponsor protocol and/or Impact Research Policy on Investigational Drug/Device Accountability.
  • Complete study documentation and maintenance of study files in accordance with sponsor requirements and Impact Research policies and procedures including, but not limited to, consent forms, source documentation, narrative notes if applicable, case report forms, and investigational material accountability forms.
  • Maintains effective and ongoing communication with sponsor, research participants, Director and PI during the course of the study.
  • Manage the day to day activities of the study including problem solving, communication and protocol management.
  • Collects and reports ongoing patient recruitment/ enrollment metrics to Director and PI.
  • Arranges secure storage of study documents that will be maintained according to Good Clinical Practice guidelines or for the contracted length of time, whichever is longer.
  • Protects the rights and welfare of all human research participants involved in research in accordance with Federal regulations
  • Cooperates with Impact Research compliance and monitoring efforts regarding the access, use, and disclosure of PHI and reports instances of noncompliance to the appropriate compliance office.
  • Other duties as assigned.

Iterative Health develops and deploys AI-powered tools for gastrointestinal (GI) care. Its main product is SKOUT®, an FDA-cleared device that helps doctors find adenomas (polyps) during GI procedures, supporting clinical judgment rather than replacing it. The company also offers AI-enabled documentation and data standardization technologies to improve the quality of patient care and to streamline clinical trials, enabling consistent reporting across institutions. By combining AI image analysis, data-driven insights, and streamlined research workflows, Iterative Health aims to improve colorectal cancer prevention and diagnosis and to extend high-quality GI care to underserved populations around the world.

Company Size

51-200

Company Stage

Series C

Total Funding

$262.2M

Headquarters

Boston, Massachusetts

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Obesity and hepatology expansion addresses $50B+ metabolic disease market with acute enrollment bottlenecks.
  • Cardiology entry via US Heart & Vascular partnership taps largest clinical trial segment with persistent gaps.
  • Gastro Health integration across 380 physicians validates scalable model for distributed healthcare network embedding.

What critics are saying

  • Medidata's Acorn platform integrates 50,000+ sites, directly commoditizing Iterative's 100-site recruitment advantage.
  • Odin Vision's SKOUT competitor achieves 10% higher adenoma detection, eroding core gastroenterology revenue.
  • Quarterly burn rate exceeds $20M post-Series C; runway exhausted by Q4 2026 without new contracts.

What makes Iterative Health unique

  • AI-embedded clinical research network with 100+ sites across four continents delivering 2x faster activation.
  • Proprietary SKOUT polyp detection technology FDA-cleared for real-time adenoma identification during endoscopy.
  • Site-centric operating model embeds research into clinical workflows, achieving 3x higher IBD enrollment rates.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Vision/Dental/ Medical Insurance

Life/Disability Insurance

Parental Leave

Stock Options

Flexible Work Hours

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-4%
TechCrunch
Mar 11th, 2026
Almost 40 new unicorns have been minted so far this year — here they are | TechCrunch

With AI igniting an investor frenzy, more startups are achieving unicorn status every month.

Business Wire
Feb 12th, 2026
Iterative Health appoints Dr. Nadege Gunn as chief medical officer for hepatology and obesity research

Iterative Health has appointed Nadege Gunn as Chief Medical Officer for Hepatology and Obesity. Dr Gunn is a board-certified gastroenterologist and hepatologist with over 15 years' experience as principal investigator on more than 100 clinical trials. At Iterative Health, Dr Gunn will lead hepatology and obesity research, overseeing medical affairs, specialized site operations, and strategic collaboration with biopharmaceutical sponsors. She is founder and former CEO of Impact Research Institute in Waco, Texas, regarded as a leading hepatology research centre, and currently serves as hepatology clinic director at Coryell Health. The Cambridge-based healthcare technology company also announced Dana Feuchtbaum's promotion from Chief Product Officer to Chief Operating Officer, where she will oversee operations across Iterative Health's global site network spanning four continents.

Morningstar
Feb 12th, 2026
Iterative Health Appoints Nadege Gunn, MD, as Chief Medical Officer, Hepatology and Obesity

Iterative Health appoints Nadege Gunn, MD, as Chief Medical Officer, Hepatology and Obesity. Provided by Business Wire Feb 12, 2026, 4:50:00 AM Leadership Appointment Solidifies Company's Vested Interest in Advancing Research in Hepatology and Obesity Iterative Health, a healthcare technology and services company powering the acceleration of clinical research, today announced the appointment of Nadege Gunn, MD, CPI, DABOM, FAASLD, as Chief Medical Officer, Hepatology and Obesity. Dr. Gunn joins Iterative Health's senior leadership team to provide strategic medical and scientific leadership across metabolic liver disease research and specialized site operations, supporting the company's rapidly expanding hepatology and obesity portfolio. Dr. Nadege Gunn will provide strategic medical and scientific leadership across metabolic liver disease research and specialized site operations, supporting Iterative Health's rapidly expanding hepatology and obesity portfolio. Dr. Gunn is a globally recognized, board-certified gastroenterologist, hepatologist, obesity medicine specialist, and physician-scientist with more than 15 years of experience as a principal investigator on over 100 early- and late-phase clinical trials. Her research expertise spans metabolic and the spectrum of liver disease, including MASH and MASLD, with a proven track record of translating complex protocols into high-performing, community-based research programs. At Iterative Health, Dr. Gunn will lead the advancement of hepatology and obesity research by overseeing medical affairs, development of specialized site operations, and strategic collaboration with biopharmaceutical sponsors and CRO partners. Her appointment underscores Iterative Health's commitment to building a leading, performance-driven research site network that expands access to innovative multispecialty therapies, while accelerating novel therapies to market faster. "Iterative Health has created an impressive foundation to advance hepatology and obesity research at scale," said Dr. Gunn. "As a practicing physician and with experience as a principal investigator, I'm excited to join a team that is deeply focused on empowering providers and extending cutting-edge clinical research into the communities that care for these patients every day." Dr. Gunn currently practices at Coryell Health, a rural community-based practice, and serves as the hepatology clinic director. She brings more than 15 years of leadership experience across clinical research operations, peer-to-peer education, and international protocol development. She is the founder and former President and CEO of Impact Research Institute in Waco, Texas, widely regarded as one of the nation's leading hepatology research centers. In addition, Dr. Gunn has held academic teaching appointments at Texas A&M University, Dell Medical School at The University of Texas at Austin, and Baylor University. Within the Chronic Liver Disease Foundation (CLDF), Dr. Gunn also serves as a key committee member of the Women in Hepatology: Initiatives, Sponsorship, and Empowerment (WHISE), dedicated to enhancing visibility and opportunities for women in the field. Dr. Gunn's appointment reflects Iterative Health's continued investment in strategic leadership and the expansion of its therapeutic focus areas. As part of this leadership growth, Iterative Health also announced the promotion of Dana Feuchtbaum from Chief Product Officer to Chief Operating Officer. In this role, Feuchtbaum will oversee operations and technology development, empowering Iterative Health's global site network spanning four continents. "For providers and sponsors alike, Dr. Gunn strengthens the clinical leadership and operational confidence behind every hepatology and obesity study we support," said Dana Feuchtbaum, Chief Operating Officer at Iterative Health. "Her appointment accelerates our ability to support increasingly complex hepatology and obesity trials at scale." About Iterative Health Iterative Health is a healthcare technology and services company powering the acceleration of clinical research to transform patient outcomes. By combining deep expertise in clinical trials with cutting-edge AI, we empower research teams and study sponsors to expand and expedite access to novel therapeutics for patients in need. The company has headquarters in Cambridge, Massachusetts, and New York, New York. For more information, visit www.iterative.health and follow us on LinkedIn for the latest company updates. Media Contact Iterative Health: Andrea Sampson Sampson Public Relations Group [email protected] The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar. Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees. Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Contract Pharma
Feb 12th, 2026
Iterative Health Adds Nadege Gunn as CMO, Hepatology and Obesity

Iterative Health adds Nadege Gunn as CMO, Hepatology and Obesity. Gunn will provide medical and scientific leadership across metabolic liver disease research and specialized site operations. February 12, 2026 Content Marketing Editor Iterative Health has hired Nadege Gunn, MD, as Chief Medical Officer (CMO), Hepatology and Obesity. Gunn currently practices at Texas-based Coryell Health, serving there as hepatology clinic director. She is the founder, and former president and CEO, of the hepatology-focused Impact Research Institute in Waco, Texas. Role of new CMO. Gunn's appointment to the Iterative Health team serves to provide strategic medical and scientific leadership in metabolic liver disease research. Gunn will also oversee specialized site operations to support Iterative Health's expanding hepatology and obesity portfolio. By strategically collaborating with biopharmaceutical sponsors and contract research organization (CRO) partners, Gunn will impact future plans for Iterative Health. These include creating a performance-driven network of research sites expanding access to multispecialty therapies, and accelerating novel therapies to market. Other Iterative Health moves. Iterative Health is also promoting Dana Feuchtbaum from Chief Product Officer to Chief Operating Officer. Feuchtbaum said that Gunn joining the team will benefit providers and sponsors alike. "Gunn strengthens the clinical leadership and operational confidence behind every hepatology and obesity study we support," Feuchtbaum said. "Her appointment accelerates our ability to support increasingly complex hepatology and obesity trials at scale." Prior Gunn experience. Gunn expressed excitement for Iterative Health's focus on "extending cutting-edge clinical research into the communities that care for these patients." "Iterative Health has created an impressive foundation to advance hepatology and obesity research at scale," Gunn said. Impact Research Institute, which Gunn founded, is recognized as a leading U.S. hepatology research center. Gunn is also a committee member of Women in Hepatology: Initiatives, Sponsorship, and Empowerment within the Chronic Liver Disease Foundation. Her academic resume includes teaching posts at Texas A&M, the University of Texas at Austin, and Baylor University.

Securities.io
Jun 21st, 2024
Ai Machine Vision Looking To Revolutionize Our Health

Machine Vision & HealthTogether with LLMs (large language models) like ChatGPT, machine vision is one of the most important recent developments in AI. The various methods used to achieve it, such as neural networks and deep learning, are now allowing computers to truly see their environment.One application of this idea is letting computers take over humans' tasks like driving or giving robots full autonomy in the real world instead of staying confined to factory floors.It is one one of the large drivers of machine vision adoption, a quickly growing market expected to reach $9.2B by 2029.But another equally important task is judging our health. Many medical diagnoses rely on doctors' visual assessments. This includes direct examination and expert-level analysis of radiography, scanners, and other medical images.In most cases, these visual inspections are somewhat subjective. A doctor will need many years of experience to become truly confident in his assessment. And until now, the complexity of each patient’s body being slightly different made it too complex for automatized measurement.This is finally changing, and many companies are now exploring deploying AI machine vision to create superior analyses of medical images.Direct Visual ExaminationWe recently explored the case of using AI to detect better than human doctor ear infections in our article “AI Poised to Become Invaluable Medical Diagnosis Tool”This can be expanded to many other pathologies; for example, Google's AI imaging can be used to diagnose 26 different skin diseases (80% of cases seen in primary care), detect diabetic retinopathy , or even predict the risk of developing diabetic retinopathy in the future .More surprisingly, AI also appears to be able to detect health issues from visual inspections that humans could not use; for example, detecting anemia (normally requiring a blood test) from a look at the eye’s retina

INACTIVE